Close Menu

Takeda

Led by a group of 10 biopharmaceutical firms, the project will use Olink's proteomic technology to look at participants' plasma levels of roughly 1,500 proteins.

The tests will be developed to identify NSCLC patients with ALK fusions and EGFR Exon20 insertion mutations who respond to mobocertinib or brigatinib.

Twist will give Takeda access to its phage display libraries to help Takeda discover and validate antibodies needed for the development of new biologics. 

The approval was based on data showing superior efficacy for Alunbrig compared to Pfizer's Xalkori, especially in patients with brain metastasis.

Cerevance, a drug discovery firm employing the transcriptome sequencing method, raised $45 million in Series B financing earlier this month.

The international firm is one of several pharmaceutical companies emphasizing new single-cell technologies to improve existing drugs and find new ones.

GenAhead said it will use the IP it had licensed from ERS for genome editing applications in pharmaceutical drug discovery and development.

The company announced agreements to use the Oncomine Dx Target Test in drug development programs with Daiichi Sankyo, Takeda, and Spectrum Pharmaceuticals.

Takeda will use Definiens' new cloud-based digital pathology platform to conduct analyses for its clinical biomarkers development programs.

HudsonAlpha researchers are expected to sequence 20,000 patient tumor and non-tumor samples for ORIEN's Avatar initiative by 2019.

Pages

Reuters reports that Germany is seeking to sequence 5 percent of patient samples that test positive for SARS-CoV-2.

23andMe and Medscape say primary care physicians are increasingly more comfortable with discussing direct-to-consumer genetic testing results.

The publisher of the Science family of journals will allow some authors to place peer-reviewed versions of their papers into publicly accessible repositories.

In Science this week: analysis of genome-wide association studies of chronic kidney disease, and more.